Novo Nordisk’s Wegovy has been approved in China for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), a severe form of non-alcoholic fatty liver disease. This marks a significant expansion of the drug’s approved uses beyond weight management. The approval in China addresses a substantial, unmet medical need, as MASH is a growing health concern within the country. Wegovy, a semaglutide-based medication, is expected to offer a new therapeutic option for patients with this condition in China. The decision is based on clinical trial data demonstrating the drug’s efficacy in reducing liver inflammation and fibrosis. This approval further solidifies Wegovy’s position as a key player in addressing both obesity and related metabolic complications globally and specifically within the Chinese market. The launch timeline in China will be announced separately by Novo Nordisk.